Effects of an oral nutritional supplement containing eicosapentaenoic acid on nutritional and clinical outcomes in patients with advanced non-small cell lung cancer: randomised trial.
Study Goal
The researchers aimed to compare the effects of an EPA-enriched oral supplement versus an isocaloric diet on nutritional, clinical, inflammatory parameters, and health-related quality of life in advanced NSCLC patients undergoing chemotherapy.
Results Summary
The EPA-enriched supplement significantly improved energy and protein intake, lean body mass, and reduced fatigue, loss of appetite, and neuropathy compared to the control group, though it did not affect chemotherapy response rate or overall survival.
Population
Advanced non-small cell lung cancer (NSCLC) patients receiving paclitaxel and cisplatin/carboplatin chemotherapy.
Effective Dosage
Not specified in the abstract.
Duration
Assessed after the first and second cycles of chemotherapy (exact duration not specified).
Interactions
None mentioned.
| Intervention | Direction | Endpoint | Population | Dosage | Impact | Claim # |
|---|---|---|---|---|---|---|
oral nutritional supplement containing EPA (ONS-EPA) | increase | energy intake | advanced NSCLC patients | p < 0.001 | significantly greater | #1 |
oral nutritional supplement containing EPA (ONS-EPA) | increase | protein intake | advanced NSCLC patients | p < 0.001 | significantly greater | #2 |
oral nutritional supplement containing EPA (ONS-EPA) | increase | lean body mass (LBM) | advanced NSCLC patients | 1.6 ± 5 kg | gained | #3 |
isocaloric diet (C) | decrease | lean body mass (LBM) | advanced NSCLC patients | -2.0 ± 6 kg | loss | #4 |
oral nutritional supplement containing EPA (ONS-EPA) | decrease | fatigue | advanced NSCLC patients | p ≤ 0.05 | decreased | #5 |
oral nutritional supplement containing EPA (ONS-EPA) | decrease | loss of appetite | advanced NSCLC patients | p ≤ 0.05 | decreased | #6 |
oral nutritional supplement containing EPA (ONS-EPA) | decrease | neuropathy | advanced NSCLC patients | p ≤ 0.05 | decreased | #7 |
oral nutritional supplement containing EPA (ONS-EPA) | no change | response rate | advanced NSCLC patients | - | no difference | #8 |
oral nutritional supplement containing EPA (ONS-EPA) | no change | overall survival | advanced NSCLC patients | - | no difference | #9 |
BACKGROUND: Nutritional interventions have shown increased energy intake but not improvement in health-related quality of life (HRQL) or prognosis in non small cell lung cancer (NSCLC) patients. Eicosapentaenoic acid has been proposed to have anti-inflammatory, anticachectic and antitumoural effects. OBJECTIVE: To compare the effect of an oral EPA enriched supplement with an isocaloric diet on nutritional, clinical and inflammatory parameters and HRQL in advanced NSCLC patients. DESIGN: Patients with advanced NSCLC were randomized to receive diet plus oral nutritional supplement containing EPA (ONS-EPA) or only isocaloric diet (C). All patients received paclitaxel and cisplatin/carboplatin treatment. Weight, body composition, dietary intake, inflammatory parameters and HRQL were assessed at baseline and after the first and second cycles of chemotherapy. Response to chemotherapy and survival were evaluated. RESULTS: Ninety two patients were analysed (46 ONS-EPA,46 C). ONS-EPA group had significantly greater energy (p < 0.001) and protein (p < 0.001) intake compared with control. Compared with baseline, patients receiving the ONS-EPA gained 1.6 ± 5 kg of lean body mass (LBM) compared with a loss of -2.0 ± 6 kg in the control (p = 0.01). Fatigue, loss of appetite and neuropathy decreased in the ONS-EPA group (p ≤ 0.05). There was no difference in response rate or overall survival between groups. CONCLUSION: Patients with NSCLC receiving ONS-EPA significantly improves energy and protein intake, body composition. and decreased fatigue, loss of appetite and neuropathy. Registered with ClinicalTrials.gov (NCT01048970).